Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CXXC1 is required for IRF4 chromatin binding and expression and regulates cellular fitness in lenalidomide-sensitive and -resistant myeloma cells

View Full Paper
Ask AI
Bookmark
Share

Authors

JTJason TaslimMAMaria AttaMBMarco Bua

Discussion

Loading...

Member takes

Overview

CXXC1 regulates IRF4 expression and cellular fitness in myeloma, suggesting it may be a therapeutic target for immunomodulatory drug resistance.

Key Points

  • CXXC1 depletion led to significant downregulation of IRF4 and MYC in myeloma cells, impacting cell proliferation.
  • Transcriptome analysis revealed alterations in oncogenic gene programs linked to unfolded protein response and DNA damage.
  • ChIP-seq showed essential co-binding of CXXC1 with IRF4 at regulatory regions of myeloma-related genes.
  • Findings highlight CXXC1 as a potential therapeutic target in both lenalidomide-sensitive and -resistant myeloma cells.

Cite This Study

Taslim et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d932https://doi.org/10.1182/blood-2025-571
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PHF19 inhibition increases IMiDs sensitivity by epigenetically regulating IRF4 and MYC in multiple myeloma2025
  2. 2Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death2025
  3. 3P300/CBP acetyltransferase inhibition and degradation disrupt oncogenic transcriptional programs and reveal epigenetic vulnerabilities in multiple myeloma2025
  4. 4Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma2025
  5. 5Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma2025